Source - SMW
Hutchison China MediTech has initiated FRUTIGA, a pivotal phase III clinical trial of fruquintinib in combination with paclitaxel (Taxol) for the treatment in advanced gastric or gastroesophageal junction adenocarcinoma patients in China. 

Chi-Med said: 'Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3. 

'This randomised, double-blind, placebo-controlled, multicentre trial is being conducted in patients with advanced gastric cancer who have progressed after first-line standard chemotherapy. 

'Advanced gastric cancer is a major medical need, particularly in Asian populations, with limited treatment options for patients who have failed first-line standard chemotherapy with 5-fluorouracil (5-FU) and platinum doublets. For gastric cancer, there are approximately 679,100 new cases and 498,000 deaths in China each year.'




Related Charts

Hutchison China Meditech (HCM)

0.00 (0.00%)
delayed 16:57PM